Table 2. Correlation between miR-144-3p and clinical features in LUAD and LUSC patients.
| LUAD | LUSC | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | All patients | miR-144-3p Low (< mediana) | miR-144-3p High (≥ mediana) | p | All patients | miR-144-3p Low (< medianb) | miR-144-3p High (≥ medianb) | p |
| n | 129 (100%) | 64 (49.61%) | 65 (50.39%) | 54 (100%) | 27 (50.00%) | 27 (50.00%) | ||
| Age (years) | 0.982 | 0.817 | ||||||
| Median (range) | 65 (48–85) | 65 (48–85) | 65 (49–84) | 64 (50–85) | 64 (51–85) | 64 (50–83) | ||
| Gender | 0.736 | 0.362 | ||||||
| Male | 93 (72.09%) | 47 (36.43%) | 46 (35.66%) | 39 (72.22%) | 21 (38.89%) | 18 (33.33%) | ||
| Female | 36 (27.91%) | 17 (17.18%) | 19 (14.73%) | 15 (27.78%) | 6 (11.11%) | 9 (16.67%) | ||
| Smoke | 0.425 | 1.000 | ||||||
| Yes | 68 (52.71%) | 36 (27.91%) | 32 (24.80%) | 36 (66.67%) | 18 (33.33%) | 18 (33.33%) | ||
| No | 61 (47.29%) | 28 (21.71%) | 33 (25.58%) | 18 (33.33%) | 9 (16.67%) | 9 (16.67%) | ||
| Pathological stagec | 0.726 | 0.141 | ||||||
| IA | 17 (13.18%) | 10 (7.75%) | 7 (5.43%) | 11 (20.37%) | 3 (5.56%) | 8 (14.81%) | ||
| IB | 34 (26.35%) | 14 (10.85%) | 20 (15.50%) | 10 (18.52%) | 6 (11.11%) | 4 (7.41%) | ||
| IIA | 23 (17.83%) | 11 (8.53%) | 12 (9.30%) | 11 (20.37%) | 8 (14.81%) | 3 (5.56%) | ||
| IIB | 32 (24.81%) | 17 (13.18%) | 15 (11.63%) | 13 (24.07%) | 7 (12.96%) | 6 (11.11%) | ||
| IIIA | 11 (8.53%) | 7 (5.43%) | 4 (3.10%) | 8 (14.81%) | 2 (3.70%) | 6 (11.11%) | ||
| IIIB | 12 (9.30%) | 5 (3.88%) | 7 (5.43%) | 1 (1.85%) | 1 (1.85%) | 0 (0.00%) | ||
| IL-1β Level | < 0.001 | 0.057 | ||||||
| Low | 64 (49.61%) | 11 (8.52%) | 53 (41.09%) | 27 (50.00%) | 10 (18.52%) | 17 (31.48%) | ||
| High | 65 (50.39%) | 53 (41.09%) | 12 (9.30%) | 27 (50.00%) | 17 (31.48%) | 10 (18.52%) | ||
| Target therapy | 0.660 | NTd | ||||||
| Yes | 64 (49.61%) | 33 (25.58%) | 31 (24.03%) | NTd | NTd | NTd | ||
| No | 65 (50.39%) | 31 (24.03%) | 34 (26.36%) | NTd | NTd | NTd | ||
Medianaa = 8.1731 Medianb = 5.8994 NTd = Not Tested
Pathological stageC was based on NCCN Guidelines Version 3.2011 NSCLC.
NCCN, National Comprehensive Cancer Network; NSCLC, non-small-cell lung cancer.